These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25090645)

  • 1. Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.
    Godeaux O; Izurieta P; Madariaga M; Dramé M; Li P; Vaughn DW
    Vaccine; 2015 Apr; 33(18):2189-95. PubMed ID: 25090645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
    Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
    BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults.
    Yang PC; Yu CJ; Chang SC; Hsieh SM; Drame M; Walravens K; Roman F; Gillard P
    J Formos Med Assoc; 2012 Jun; 111(6):333-9. PubMed ID: 22748624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
    Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA
    Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
    Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
    BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
    Díez-Domingo J; Baldó JM; Planelles-Catarino MV; Garcés-Sánchez M; Ubeda I; Jubert-Rosich A; Marès J; Garcia-Corbeira P; Moris P; Teko M; Vanden Abeele C; Gillard P
    Influenza Other Respir Viruses; 2015 Mar; 9(2):68-77. PubMed ID: 25652873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
    Song JY; Choi MJ; Noh JY; Choi WS; Cheong HJ; Wie SH; Lee JS; Woo GJ; Lee SH; Kim WJ
    Hum Vaccin Immunother; 2017 May; 13(5):1190-1197. PubMed ID: 27996363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
    Hwang SJ; Chang SC; Yu CJ; Chan YJ; Chen TJ; Hsieh SL; Lai HY; Lin MH; Liu JY; Ong G; Roman F; Dramé M; Bock HL; Yang PC
    J Formos Med Assoc; 2011 Dec; 110(12):780-6. PubMed ID: 22248833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
    Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
    Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong.
    Chu DW; Kwong AS; Tsui WW; Wang JH; Ngai CK; Wan PK; Ong G; Tang HW; Roman F; Dram M; Bock HL
    Hong Kong Med J; 2011 Feb; 17(1):39-46. PubMed ID: 21282825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.